Citations 2
COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study
Fazio, Nicola , Gervaso, Lorenzo , Hálfdánarson, Þorvarður R. , Eiring, Rachel A. , Stocchetti, Benedetta Lombardi , Grozinsky‐Glasberg, Simona , Gross, David J. , Walter, Thomas , Robelin, Patrick, Bagnardi, Vincenzo , Antonuzzo, Lorenzo , Sparano, Clotilde , Gelsomino, Fabio, Rossi, Maura , Cives, Mauro , Kakil, I. R., Hamid, Hytam, Squadroni, M., Koumarianou, Anna, Boselli, S., Tamayo, Darina, Mazzon, Cristina, Rubino, Manila , Spada, Francesca , Sonbol, Mohamad, Grozinsky-Glasberg, Simona , Sparano, Clotilde , Massironi, Sara , Hofland, Johannes , Halfdanarson, Thorvardur R , Eiring, Rachel A , Antonuzzo, Lorenzo , Sonbol, Mohamad Bassam , Pusceddu, Sara , Prinzi, Natalie , Lombard‐Bohas, Catherine , Frassoni, Samuele , Gelsomino, Fabio , Bongiovanni, Alberto , Ranallo, Nicoletta , Tafuto, Salvatore , Chirco, Alessandra, Salvia, Anna La , Hernando, Jorge , Hofland, Johannes
Endocrine-Related Cancer | March 17, 2023 | Volume: 30 | Issue: 6 | Pages: No page available
We conducted a retrospective/prospective worldwide study on patients with neuroendocrine neoplasms (NENs) and a molecularly proven SARS-CoV-2 positivity. Preliminary results regarding 85 patients of the INTENSIVE study have been published in 2021. Now we are reporting the 2-year analysis.Here, we are reporting data from consecutive patients enrolled between 1 June 2020, and 31 May 2022. Among the 118 contacted centers, 25 were active to enroll and 19 actively recruiting at the time of data cut-off for a total of 280 patients enrolled. SARS-CoV-2 positivity occurred in 47.5% of patients in 2020, 35.1% in 2021, and 17.4% in 2022. The median age for COVID-19 diagnosis was 60 years. Well-differentiated tumors, non-functioning, metastatic stage, and gastroenteropancreatic (GEP) primary sites represented most of the NENs. COVID-19-related pneumonia occurred in 22.8% of the total, with 61.3% of them requiring hospitalization; 11 patients (3.9%) needed sub-intensive or intensive care unit therapies and 14 patients died (5%), in 11 cases (3.9%) directly related to COVID-19. Diabetes mellitus and age at COVID-19 diagnosis > 70 years were significantly associated with COVID-19 mortality, whereas thoracic primary site with COVID-19 morbidity. A significant decrease in both hospitalization and pneumonia occurred in 2022 vs 2020. In our largest series of NEN patients with COVID-19, the NEN population is similar to the general population of patients with NEN regardless of COVID-19. However, older age, non-GEP primary sites and diabetes mellitus should be carefully considered for increased COVID-19 morbidity and mortality. Relevant information could be derived by integrating our results with NENs patients included in other cancer patients with COVID-19 registries.
INTENSIVE: InterNaTional rEgistry oN Sars-cov-2 posItiVe nEuroendocrine neoplasm patients.
Spada, Francesca , Capdevila, Jaume , Hofland, Johannes , Koumarianou, Anna, Rossi, Maura , Boselli, S., Tamayo, Darina, Laffi, Alice , Rubino, Manila , Hofland, Johannes , Gervaso, Lorenzo , Salvia, Anna La , García‐Carbonero, Rocio , Hernando, Jorge , Herder, Wouter W. de , Bagnardi, Vincenzo , Sonbol, Mohamad Bassam , Fazio, Nicola , Hálfdánarson, Þorvarður R.
Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 15_suppl | Pages: e16205-e16205
10.1200/jco.2021.39.15_suppl.e16205
e16205 Background: Data about neuroendocrine neoplasms (NENs) patients with SARS-CoV-2 are scanty and specific indications for clinical practice are missing. Our aim is to create an international registry about NENs patients affected by SARS-CoV-2 positivity to give a worldwide representation of the situation. Methods: This is an observational retrospective/prospective multicenter survey based on a direct email invitation. All types of NEN are eligible except SCLC and MiNEN. Patients fulfilling the inclusion criteria from March 1st, 2020 up to the end pf pandemic will be recruited. Electronic CRFs are filled out using the REDCap database. Local Institutional Review Board approval is required before data entry. Results: Eighty-one centers, 24 in and 57 outside Italy, representing 39 countries and 5 continents, were contacted. Fourteen centers did not respond and 15 declined the invitation. Among the remaining 52, 6 centers are currently recruiting and 8 are active but not recruiting yet. As of the current abstract submission deadline, 67 patients have been included, mostly GEP-NET (75%), non-functioning (86%), metastatic (85%) and on active treatment [47% somatostatin analogs (SSAs), 10% everolimus, 12% tirosin-kinase inhibitors (TKIs), 10% peptide receptor radionuclide therapy (PRRT), 15% chemotherapy]. Median age at NEN diagnosis was 57 years whilst the median age at SARS-CoV-2 diagnosis was 62 years. Almost all patients reported COVID-19-related symptoms, more commonly fever (67% of patients), cough (55%) and dyspnea (51%), in 28% of cases exertional and in 22% at rest. More than one third of patients (n, 24) had a pneumonia. The most common therapies for COVID-19 were antibiotics, steroids and hydroxychloroquine. Eleven patients (16%) needed oxygen therapy, three (4%) sub-intensive care and none intensive care. Fifty-six patients (84%) clinically recovered, six (9%) with sequelae, whereas five (7%) died. Among these latter 4 had a NET and 1 a NEC, and no patients have been receiving chemotherapy. With regard to the anti-tumor therapy no change occurred in 66% of patients, temporary interruption in 30%, and definitive discontinuation in 3%, 2% missing. Conclusions: Most of the NEN patients completely recovered from COVID-19, in many cases without any anti-tumor therapy adjustment. No clear correlations were observed with type, primary site and treatment of NEN. The recruitment is ongoing.